Aardvark Therapeutics, Inc. (AARD) Price & Analysis

Compare

37 Followers

AARD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.88 - $19.58

Previous CloseN/A

VolumeN/A

Average Volume (3M)84.83K

Market Cap

$173.58M

Enterprise Value$152.11M

Total Cash (Recent Filing)$141.82M

Total Debt (Recent Filing)$645.00K

Price to Earnings (P/E)―

Beta1.52

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding21,696,894

10 Day Avg. Volume143,865

30 Day Avg. Volume84,828

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.65K

Enterprise Value/Ebitda-3.73

Forecast

1Y Price Target

$32.60

Price Target Upside318.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsTopline data from the Ph3 HERO study represents the next key catalyst for Aardvark Therapeutics.

Product DevelopmentAardvark's focus on hypothalamic obesity and Prader-Willi Syndrome is attractive, with existing clinical data showing the therapeutic impact of ARD-101.

ValuationAardvark Therapeutics is considered an appetizing investment opportunity due to its current valuation being significantly lower compared to peers.

Bears Say

Market CompetitionThe recent approval of Soleno's Vykat XR in PWS highlights a supportive FDA, which could increase competitive pressure for ARD-101.

Patient PopulationThe pricing and competitive landscape dynamics appear favorable for Aardvark, even if the target patient population is small.

Aardvark Therapeutics, Inc. News

Aardvark Therapeutics reports inducement grants under Nasdaq listing rule

Aardvark Therapeutics (AARD) announced that on August 28, 2025, two new employees were granted inducement awards consisting of...

9d ago

AARD

Aardvark Therapeutics price target lowered to $25 from $26 at BofA

BofA analyst Tim Anderson lowered the firm’s price target on Aardvark Therapeutics (AARD) to $25 from $26 and...

16d ago

AARD

Aardvark Therapeutics Updates Corporate Presentation on Strategy

Aardvark Therapeutics, Inc. ( ($AARD) ) has provided an announcement. On September 2, 2025, Aardvark Therapeutics, Inc. updated...

10d ago

AARD

Aardvark Therapeutics Advances Clinical Trials and Financials

Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q2 earnings. Here is a breakdown of the information...

17d ago

AARD

Aardvark Therapeutics price target lowered to $19 from $20 at RBC Capital

RBC Capital lowered the firm’s price target on Aardvark Therapeutics (AARD) to $19 from $20 and keeps an...

1M ago

AARD

Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c)

“Aardvark has made significant progress across our pipeline, and we are well-positioned to unlock the full potential of...

1M ago

AARD

Buy Rating for Aardvark Therapeutics, Inc. Driven by Promising ARD-201 Obesity Treatment Potential

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aardvark Therapeutics, Inc. today and set a price...

1M ago

AARD

Aardvark Therapeutics Reveals Promising Preclinical Data for ARD-201

Aardvark Therapeutics, Inc. ( ($AARD) ) has shared an announcement. On August 12, 2025, Aardvark Therapeutics announced promising...

1M ago

AARD

Aardvark Therapeutics announces preclinical data on ARD-201

Aardvark Therapeutics (AARD) announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic...

1M ago

AARD

Aardvark Therapeutics announces inducement grants under Nasdaq listing rule

Aardvark Therapeutics (AARD) announced that between July 8-14, 2025, two new employees were granted inducement awards consisting of...

2M ago

AARD

Aardvark Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $40 price target The emerging...

3M ago

AARD

Aardvark Therapeutics participates in 2025 United in Hope Conference

Aardvark Therapeutics (AARD) announced that members of its team will join the Prader-Willi syndrome community at the 2025...

3M ago

AARD

Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO

Aardvark Therapeutics (AARD) announced the appointments of key members of its leadership team, including Timothy Kieffer as chief...

4M ago

AARD

Aardvark Therapeutics Inc trading resumes

09:40 EDT Aardvark Therapeutics (AARD) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

4M ago

AARD

AARD FAQ

What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?

Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.

What is Aardvark Therapeutics, Inc.’s market cap?

Aardvark Therapeutics, Inc.’s market cap is $173.58M.

When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Aardvark Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Aardvark Therapeutics, Inc. overvalued?

According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aardvark Therapeutics, Inc. pay dividends?

Aardvark Therapeutics, Inc. does not currently pay dividends.

What is Aardvark Therapeutics, Inc.’s EPS estimate?

Aardvark Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aardvark Therapeutics, Inc. have?

Aardvark Therapeutics, Inc. has 21,696,894 shares outstanding.

What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?

Currently, no hedge funds are holding shares in AARD

Aardvark Therapeutics, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

635.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Aardvark Therapeutics, Inc. (AARD) Earnings & Revenues

Historic Earnings Reports

AARD Stock 12 Month Forecast

Average Price Target

$32.60

▲(318.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,15.043076923076924,17.956153846153846,20.869230769230768,23.78230769230769,26.69538461538461,29.60846153846154,32.52153846153846,35.434615384615384,38.347692307692306,41.26076923076923,44.17384615384615,47.08692307692308,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,13.704615384615385,15.27923076923077,16.853846153846156,18.42846153846154,20.003076923076925,21.57769230769231,23.152307692307694,24.72692307692308,26.301538461538463,27.876153846153848,29.450769230769232,31.025384615384617,{"y":32.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,12.65846153846154,13.186923076923078,13.715384615384616,14.243846153846155,14.772307692307693,15.30076923076923,15.829230769230769,16.357692307692307,16.886153846153846,17.414615384615384,17.943076923076923,18.47153846153846,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.3,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >